Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Aude, Houchard"'
Autor:
Janet Brown, Brooke Harrow, Anne Marciniak, Christine McCarthy, Aude Houchard, Lori Cirneanu, Andrew Protheroe
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 2, Pp 195-207 (2024)
Abstract Background and Objective The tyrosine kinase inhibitors cabozantinib and axitinib have been widely used in England to treat advanced renal cell carcinoma following prior vascular endothelial growth factor-targeted therapy, but data on real-w
Externí odkaz:
https://doaj.org/article/82bbb121fd2349b08c067d0b6d0b35bf
Autor:
Piero Ferolla, Alfredo Berruti, Francesca Spada, Maria Pia Brizzi, Toni Ibrahim, Riccardo Marconcini, Dario Giuffrida, Vito Amoroso, Anna La Salvia, Vanja Vaccaro, Antongiulio Faggiano, Annamaria Colao, Marco Volante, Simona Ghizzoni, Paola Mazzanti, Aude Houchard, Nicola Fazio
Publikováno v:
Neuroendocrinology. 113:332-342
Introduction: Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking. ATLANT (NCT02698410)
Autor:
Jorge Hernando, Teodora Kolarova, Chris Verslype, Gregory Kaltsas, Aude Houchard, Delphine Gueguen, Wouter W. De Herder
Publikováno v:
Journal of Neuroendocrinology. Wiley-Blackwell Publishing Ltd
Scientia
Scientia
Injection experience; Neuroendocrine tumors; Somatostatin analog Experiència en injecció; Tumors neuroendocrins; Anàleg de la somatostatina Experiencia en inyección; Tumores neuroendocrinos; Análogo de la somatostatina Lanreotide autogel/depot (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d05a9edefabc90b09fc14a39313ca2c
https://pure.eur.nl/en/publications/47fbcc12-995d-4bea-9984-00fecf75eb4f
https://pure.eur.nl/en/publications/47fbcc12-995d-4bea-9984-00fecf75eb4f
Autor:
Diego Ferone, Wendy Martin, Jessica Williams, Aude Houchard, Christelle Pommie, Antonio Ribeiro-Oliveira, Ashley B Grossman
Publikováno v:
Endocrine Abstracts.
Autor:
Thierry Brue, Maria Fleseriu, Ariel Barkan, Edouard Duquesne, Aude Houchard, Pilar Schneider Maria del, Antonio Ribeiro-Oliveira, Shlomo K. Melmed
Publikováno v:
Endocrine Abstracts.
Autor:
null Jorge Hernando, null Teodora Kolarova, null Chris Verslype, null Gregory Kaltsas, null Aude Houchard, null Delphine Gueguen, null Wouter W. De Herder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cb93fcde48242445d54e7eb540af5d0
https://doi.org/10.1111/jne.13281/v3/response1
https://doi.org/10.1111/jne.13281/v3/response1
Autor:
Philippe Ruszniewski, Tahir Shah, Ulrich Frank Pape, Aude Houchard, Marianne Pavel, C. Lombard-Bohas, Xuan-Mai Truong Thanh, Francesco Panzuto, Ivan Borbath, Jarosław B. Ćwikła, Jaume Capdevila
Publikováno v:
Scientia
European journal of cancer (Oxford, England : 1990), Vol. 157, no.157, p. 403-414 (2021)
European journal of cancer (Oxford, England : 1990), Vol. 157, no.157, p. 403-414 (2021)
Lanreotide; Progression-free survival; Somatostatin Lanreótido; Supervivencia libre de progresión; Somatostatina Lanreòtid; Supervivència lliure de progressió; Somatostatina Introduction This prospective, single-arm, phase 2 study assessed the e
Autor:
Marek Bolanowski, Beata Kos-Kudła, Marta Bartmanska, Marek Ruchała, Aude Houchard, Wojciech Zgliczyński, Przemysław Witek, Alicja Hubalewska-Dydejczyk
Publikováno v:
Endokrynologia Polska. 72:512-519
Introduction: Patients with acromegaly have substantially reduced quality of life (QoL). This study evaluated QoL in patients with acromegaly treated with lanreotide autogel. Material and methods: This was a prospective, non-interventional, observati
Autor:
Marianne Pavel, Aude Houchard, Dominique Clement, Matthew H. Kulke, Lucie Keeber, Martin O. Weickert, Rajaventhan Srirajaskanthan
Publikováno v:
Clinical Therapeutics. 43:1779-1785
Reported incidences of neuroendocrine tumors (NETs) appear to be increasing, possibly due to greater disease awareness and increased accuracy of diagnosis. Approximately 20% of patients with NETs develop carcinoid syndrome (CS), which arises from ele
Autor:
Dermot O’Toole, Pamela L. Kunz, Susan M. Webb, Grace Goldstein, Sheila Khawaja, Mark McDonnell, Sandra Boiziau, Delphine Gueguen, Aude Houchard, Antonio Ribeiro-Oliveira, Ally Prebtani
Publikováno v:
Advances in therapy.
Real-world data evaluating patients' injection experiences using the latest devices/formulations of the long-acting (LA) somatostatin analogs (SSAs) lanreotide Autogel/Depot (LAN; Somatuline®) and octreotide LA release (OCT; Sandostatin®) are limit